Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BH011
- Development stage
- Phase 2
- Lead developer
- Zhuhai Beihai Biotech
- Modality
- Small Molecules
- Administration
- Intravesical
01
Overview
BH011 is a novel formulation of docetaxel developed for intravesical administration in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who have failed Bacillus Calmette-Guérin (BCG) therapy. The drug is being investigated as an alternative to radical cystectomy, aiming to provide a less invasive therapeutic option for this patient population. Docetaxel is a microtubule inhibitor that disrupts cell division, leading to cancer cell death. The current clinical studies are focused on evaluating the safety, tolerability, and preliminary efficacy of BH011 in NMIBC patients after BCG failure[1][2][8].
- Other names
- BH011BH-011BH 011
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on BH011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BH011.